



Suppl. Fig. 17. Identification of AML subclones using mitochondrial DNA (mtDNA) mutations. A Longitudinal mtDNA-based single cell T cell chimerism in AML1010, AML1011 and AML1026 throughout treatment with decitabine and ipilimumab. B Longitudinal dynamics of cell types throughout the ETCTN/CTEP 10026 study in the five studied AML cases. In AML1026 blue indicates all T cells. C Identification of mtDNA-derived subclones in four studied AML cases. D Longitudinal dynamics of AML subclones through treatment on ETCTN/CTEP 10026. Dotted lines represent clones that diminish over time, while solid lines indicate clones with increase in representation. E Longitudinal dynamics of mtDNA-based subclusters in AML1026 across different phenotypic compartments, which suggests an increase of subclonal complexity throughout treatment. Screening – baseline sample prior to decitabine/ipilimumab treatment. Decitabine – sample after decitabine monotherapy priming cycle. C1/C2/C4/C10 – number of treatment cycles of decitabine/ipilimumab. EOT – end of treatment.